Drive mechanish for drug delivery devices

Details for Australian Patent Application No. 2004216827 (hide)

Owner Sanofi-Aventis Deutschland GmbH

Inventors Perkins, Robert; Plumptre, David Aubey; Veasey, Robert Frederick

Agent Watermark

Pub. Number AU-B-2004216827

PCT Pub. Number WO2004/078239

Priority 0304822.0 03.03.03 GB

Filing date 3 March 2004

Wipo publication date 16 September 2004

Acceptance publication date 7 January 2010

International Classifications

A61M 5/315 (2006.01) Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way - Pistons

A61M 5/24 (2006.01) Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way - Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or cartridges, e.g. automatic

Event Publications

22 September 2005 PCT application entered the National Phase

  PCT publication WO2004/078239 Priority application(s): WO2004/078239

22 November 2007 Assignment before Grant

  DCA Design International Ltd. The application has been assigned to Sanofi-Aventis Deutschland GmbH

7 January 2010 Application Accepted

  Published as AU-B-2004216827

6 May 2010 Standard Patent Sealed

1 July 2010 Amendment Made

  The nature of the amendment is: Amend the invention title to read Drive mechanism for drug delivery devices

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004216828-Improvements in and relating to drive mechanisms suitable for use in drug delivery devices

2004216823-Pharmaceutical preparations containing thiazolidinediones for the treatment or prevention of IP-10 mediated diseases